ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics


ClearPoint Neuro, Inc. (CLPT): $19.62

0.70 (+3.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CLPT POWR Grades


  • CLPT scores best on the Momentum dimension, with a Momentum rank ahead of 51.62% of US stocks.
  • The strongest trend for CLPT is in Stability, which has been heading down over the past 47 weeks.
  • CLPT's current lowest rank is in the Stability metric (where it is better than 12.89% of US stocks).

CLPT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CLPT is 0.31 -- better than just 23.58% of US stocks.
  • CLPT's price/sales ratio is 28.83; that's higher than the P/S ratio of 92.42% of US stocks.
  • ClearPoint Neuro Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -13.03%, greater than the shareholder yield of just 17.43% of stocks in our set.
  • Stocks that are quantitatively similar to CLPT, based on their financial statements, market capitalization, and price volatility, are BMRA, PCTI, SIGA, FLUX, and THRM.
  • CLPT's SEC filings can be seen here. And to visit ClearPoint Neuro Inc's official web site, go to www.clearpointneuro.com.

CLPT Valuation Summary

  • In comparison to the median Healthcare stock, CLPT's price/earnings ratio is 223.84% lower, now standing at -45.2.
  • Over the past 113 months, CLPT's EV/EBIT ratio has gone down 39.6.
  • Over the past 113 months, CLPT's price/sales ratio has gone up 20.9.

Below are key valuation metrics over time for CLPT.

Stock Date P/S P/B P/E EV/EBIT
CLPT 2021-08-31 28.8 8.8 -45.2 -45.6
CLPT 2021-08-30 27.7 8.5 -43.6 -43.9
CLPT 2021-08-27 28.1 8.6 -44.2 -44.6
CLPT 2021-08-26 26.7 8.2 -41.9 -42.0
CLPT 2021-08-25 27.2 8.3 -42.8 -43.0
CLPT 2021-08-24 27.3 8.4 -42.9 -43.1

CLPT Growth Metrics

  • Its 5 year net income to common stockholders growth rate is now at 30.46%.
  • Its 5 year net cashflow from operations growth rate is now at 50.93%.
  • The 3 year net income to common stockholders growth rate now stands at 12.29%.
CLPT's revenue has moved up $8,012,476 over the prior 37 months.

The table below shows CLPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 14.67863 -9.617486 -9.347127
2021-03-31 13.74341 -7.607604 -7.265175
2020-12-31 12.829 -7.807 -6.782
2020-09-30 12.32312 -5.870809 -6.845807
2020-06-30 11.7314 -5.468459 -6.484543
2020-03-31 11.86001 -4.570448 -6.37389

CLPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLPT has a Quality Grade of C, ranking ahead of 39.1% of graded US stocks.
  • CLPT's asset turnover comes in at 0.297 -- ranking 131st of 182 Medical Equipment stocks.
  • IVC, MLSS, and CFMS are the stocks whose asset turnover ratios are most correlated with CLPT.

The table below shows CLPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.297 0.680 -0.308
2021-03-31 0.370 0.694 -0.245
2020-12-31 0.524 0.711 -0.240
2020-09-30 0.613 0.740 -0.337
2020-06-30 0.652 0.704 -0.416
2020-03-31 0.763 0.674 -0.596

CLPT Price Target

For more insight on analysts targets of CLPT, see our CLPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.00 Average Broker Recommendation 1.5 (Moderate Buy)

CLPT Stock Price Chart Interactive Chart >

Price chart for CLPT

CLPT Price/Volume Stats

Current price $19.62 52-week high $31.29
Prev. close $18.92 52-week low $4.87
Day low $18.64 Volume 250,700
Day high $19.71 Avg. volume 386,240
50-day MA $18.92 Dividend yield N/A
200-day MA $19.07 Market Cap 438.84M

ClearPoint Neuro, Inc. (CLPT) Company Bio


ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.


CLPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CLPT Latest Social Stream


Loading social stream, please wait...

View Full CLPT Social Stream

Latest CLPT News From Around the Web

Below are the latest news stories about ClearPoint Neuro Inc that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

ClearPoint Neuro Reports Second Quarter 2021 Results

Record Case Volume Supported Clinically During the QuarterSOLANA BEACH, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2021. Second Quarter Highlights Reported revenue of $3.4 million, a 38% year-over-year increase;Clinical team supported a record 249 cases, a 98% year-over- year increa

Yahoo | August 10, 2021

ClearPoint Neuro, Inc. Announces Strategic and Commercial Partnership with European Surgical Equipment Leader adeor medical AG

SOLANA BEACH, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has entered into a strategic and commercial partnership with German-based surgical equipment leader adeor medical AG for powered neurosurgical drill solutions. Under the terms of the agreement, ClearPoint Neuro will act as the distributor in the United States for adeor’s recently FDA-cleared Ve

Yahoo | August 9, 2021

ClearPoint Neuro, Inc. Announces Installation of ClearPoint® Neuro Navigation System at Hôpital Fondation Rothschild in Paris

SOLANA BEACH, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the installation of its ClearPoint Neuro Navigation System at Hôpital Fondation Rothschild in Paris, France. “We have embarked on a promising clinical trial collaboration with ClearPoint Neuro for laser interstitial thermal ablations in pediatric neurosurgical brain pathologies. The use of ClearPo

Yahoo | August 4, 2021

ClearPoint Neuro to Announce Second Quarter 2021 Results August 10, 2021

SOLANA BEACH, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 second quarter on Tuesday, August 10, 2021, after the market close. Investors and analysts are invited to listen to a live broadcast review of the Company's 2021 second quarter on Tuesday, August 10, 2021 at 4:30 p.m. Eastern time

Yahoo | August 2, 2021

What You Need To Know About ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Investor Composition

A look at the shareholders of ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) can tell us which group is most powerful...

Yahoo | July 23, 2021

Read More 'CLPT' Stories Here

CLPT Price Returns

1-mo 17.41%
3-mo 4.31%
6-mo -8.96%
1-year 233.11%
3-year 1,301.43%
5-year N/A
YTD 23.47%
2020 231.04%
2019 205.73%
2018 -42.91%
2017 -19.12%
2016 -77.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9321 seconds.